Key Insights• According to the research report, "China Point of Care Diagnostics Market Outlook, 2031," published by Bonafide Research, the China Point of Care Diagnostics Market is expected to reach a market size of more than 6.93 Billion by 2031.• The Chinese market is moving away from traditional lateral flow assays toward microfluidic Lab-on-a-Chip systems and rapid isothermal nucleic acid amplification testing. Breakthroughs include single-use microfluidic cartridges capable of running multiplex PCR tests in under 15-20 minutes without requiring complex central lab infrastructure.• China’s National Health Commission (NHC) policies and hospital modernization budgets are driving decentralized testing. Acute care applications such as emergency cardiac marker screening (e.g., high-sensitivity troponin) and rapid sepsis risk panels are being deployed directly at bedside and in rural tier-2/tier-3 community health centers.• Domestic Chinese manufacturers are leveraging government domestic-preference policies to scale local biosensor chip production, driving down test cartridge manufacturing costs. This localization push has narrowed the price gap between import brands and local alternatives.Market Outlook• Government initiatives aimed at primary healthcare infrastructure and regional medical centers will continue to shift diagnostic volume away from centralized tertiary hospitals to outpatient, emergency, and community health centers. Demand will expand rapidly for point-of-care panels that test for multiple respiratory pathogens simultaneously (e.g., Flu A/B, RSV, and COVID-19) in a single patient sample at the clinic level.• Associations include China Association for In Vitro Diagnostics (CAIVD), National Health Commission (NHC), and the National Medical Products Administration (NMPA). Key companies consist of Roche Diagnostics, Abbott Laboratories, Danaher Corporation (Cepheid), Sansure Biotech, Wondfo Biotech, Mindray Medical, Guangzhou Bioerm, and Orient Gene.Market DynamicsDriver: Rapidly aging demographics and subsidized healthcare modernizationChina faces an accelerating demographic shift toward an aging population, alongside a massive surge in chronic lifestyle diseases (such as diabetes and cardiovascular ailments) and infectious disease burdens.

To address this, government health authorities have heavily prioritized decentralized healthcare modernization, injecting substantial capital into local clinics, grassroots community health centers, and regional hospitals. This strategic push fuels sustained, high-volume demand for rapid, point-of-care (POC) testing platforms that decentralize screening and ease the burden on major urban medical hubs.Challenge: Rigorous In-country clinical trials and complex NMPA scrutinyCommercializing a point-of-care diagnostic or in-vitro diagnostic (IVD) device in China requires navigating strict regulatory oversight by the National Medical Products Administration (NMPA). Unlike regions that easily accept foreign clinical data, China often mandates localized clinical trials performed on domestic patient cohorts within NMPA-certified clinical testing centers. This requirement, paired with extensive technical dossier reviews and rigorous local sample testing, leads to prolonged time-to-market windows, high initial compliance expenditure, and steep regulatory entry barriers for overseas manufacturers.Trend: Aggressive domestic substitution (Guochan) and digital health integrationDriven by government procurement preferences and national self-sufficiency initiatives, there is a pronounced market shift toward domestic innovation (Guochan) and localized manufacturing partnerships. Concurrently, advanced POC systems such as microfluidic and cartridge-based molecular platforms are increasingly integrated with digital hospital ecosystems, mobile health applications, and national cloud-based disease surveillance networks. This allows decentralized test outcomes to sync directly into regional epidemiological tracking platforms for real-time public health monitoring.Segment Analysis China Point of Care Diagnostics By Product• Glucose monitoring in China is evolving from conventional finger-stick meters toward connected and hybrid monitoring systems that combine measurement, digital display, data management, and increasingly automated interpretation.

A notable example is NMPA's approval of a combined glucometer incorporating invasive and non-invasive measurement modules, illustrating domestic innovation around reducing the burden of repeated blood sampling. This creates room for products that emphasize painless or lower-burden monitoring, smartphone connectivity, and integration with broader diabetes-management workflows.• Infectious-disease POC testing in China is moving beyond simple rapid screening toward molecular and multiplex platforms capable of identifying pathogens with greater specificity. The strongest product differentiation increasingly comes from shortening the complete diagnostic workflow from specimen preparation through amplification or immunodetection to result interpretation rather than simply reducing assay time.• Pregnancy and fertility tests represent a highly decentralized segment because consumers can perform many reproductive-health assessments without visiting a diagnostic laboratory. Chinese product development increasingly extends beyond conventional pregnancy strips toward ovulation and fertility-window tests, digitally interpreted readers, and formats designed for repeated home use. Self-testing is receiving explicit regulatory attention in China, including standards work concerning manufacturer-supplied information and labeling for self-testing IVD reagents.• Hematology POC products bring selected blood measurements closer to the patient through compact analyzers, cartridges, and simplified sample-processing workflows. Applications can include hemoglobin, hematocrit, coagulation-related parameters, and other measurements where rapid information can complement conventional laboratory analysis.

In China, the segment is increasingly shaped by the country's risk-based IVD regulatory system, under which registration requirements vary according to device classification. • Cardiometabolic monitoring in China increasingly connects glucose, lipid, coagulation, and related measurements with longer-term disease-management workflows. The market is particularly receptive to systems that combine measurement with digital data capture, remote monitoring, and patient-facing feedback, allowing POC results to become part of a longitudinal health record. Domestic innovation is also extending into alternative glucose-monitoring approaches, as demonstrated by NMPA's approval of a combined invasive/non-invasive glucometer.• Urinalysis POC products benefit from the simplicity of urine collection and the ability of reagent strips to assess multiple parameters within one testing workflow. The segment spans basic visual dipsticks and reader-assisted systems capable of standardized interpretation and electronic result capture. In China, the opportunity is particularly relevant to decentralized screening because a simple strip can provide preliminary information while more complex testing remains available through clinical laboratories.• Cholesterol test strips occupy a bridge between conventional laboratory lipid testing and near-patient cardiometabolic screening. Their appeal lies in rapid capillary-sample testing that can be incorporated into consultations, community health activities, pharmacies, or home monitoring.

Chinese product development is increasingly oriented toward compact readers, simplified sampling, digital result storage, and integration with broader cardiovascular-risk management rather than providing a standalone cholesterol value. • Other products encompass cardiac biomarkers, inflammatory markers, electrolytes, blood gases, coagulation tests, toxicology, reproductive biomarkers, and multi-analyte platforms. This category is particularly important for Chinese POC innovation because a single instrument can potentially support multiple assays through interchangeable cartridges, creating a more laboratory-like diagnostic environment in compact form. The regulatory framework explicitly covers reagents, reagent kits, calibrators, control materials, and systems used independently or with instruments, while NMPA also provides special review mechanisms for innovative IVDs. China Point of Care Diagnostics By Technology/Platform• Lateral flow assays remain highly compatible with decentralized Chinese diagnostics because they combine portability, rapid operation, and limited equipment requirements. They are useful across infectious-disease screening, pregnancy, fertility, and other rapid-test applications, with both professional and self-testing configurations. An important market characteristic is the increasing formalization of self-testing requirements: China's standards system is developing specific manufacturer-information requirements for self-testing IVD reagents.• PCR and isothermal nucleic-acid amplification are enabling molecular testing to move closer to the patient through compact analyzers and integrated cartridges. These platforms can combine sample preparation, amplification, and detection into a contained workflow, making them particularly valuable for infectious-disease applications where rapid pathogen identification can influence immediate management.• Microfluidics and immunoassays enable increasingly sophisticated laboratory processes to be miniaturized into cartridges and compact analyzers.

Microfluidics can manage small sample volumes and integrate preparation, reaction, separation, and detection, while immunoassays support biomarkers such as proteins, hormones, antigens, and antibodies. In China, these technologies are particularly relevant to platforms attempting to reproduce selected laboratory capabilities closer to the patient.• Dipsticks and test strips remain one of the most accessible POC formats in China because they require minimal equipment and can be deployed directly at the testing site. Urinalysis, glucose monitoring, cholesterol screening, and other applications can use disposable strips, while reader-based formats add automated interpretation and digital record capture. The technology is therefore evolving from simple visual screening toward connected, instrument-assisted workflows. China Point of Care Diagnostics By End-User• Chinese hospitals and critical-care facilities use POC diagnostics when rapid information can complement centralized laboratory testing during acute clinical situations. Emergency departments, intensive-care units, operating environments, and other high-dependency areas can benefit from tests that reduce delays associated with specimen transport and centralized processing. The distinctive feature is the integration of POC into a formally regulated medical-device environment: IVD products are subject to risk-based registration or filing, quality-management requirements, and lifecycle responsibilities extending from development through use.• Clinical and diagnostic laboratories remain an important quality and oversight component of China's POC ecosystem even when testing occurs outside the conventional laboratory.

Their role can include method verification, quality control, operator training, instrument management, result review, and confirmation of findings when required. This becomes increasingly significant as POC systems adopt molecular, immunoassay, microfluidic, and multi-analyte technologies that resemble selected laboratory workflows.• Home care and self-testing are expanding China's POC ecosystem through glucose monitoring, pregnancy and fertility testing, selected infectious-disease tests, and other consumer-oriented applications. The defining characteristic is the transfer of several steps traditionally performed by healthcare professionals specimen collection, testing, interpretation, and initial decision-making to the user. China is developing specific regulatory and standards infrastructure for self-testing IVDs, including requirements concerning manufacturer-supplied information and labeling.Considered in this report• Historic Year: 2020• Base year: 2025• Estimated year: 2026• Forecast year: 2031Aspects covered in this report• Point of Care Diagnostics Market with its value and forecast along with its segments• Various drivers and challenges• On-going trends and developments• Top profiled companies• Strategic recommendationBy Product• Glucose Monitoring Kits• Infectious Diseases Testing Kits• Pregnancy And Fertility Testing Kits• Hematology Testing Kits• Cardiometabolic Monitoring Kits• Urinalysis Testing Kits• Cholesterol Test Strips• Other ProductsBy Technology/Platform• Lateral Flow Assays• Molecular Diagnostics (PCR/INAAT)• Microfluidics & Immunoassays• Dipsticks & Test StripsBy End-User• Hospitals & Critical Care Centers• Clinical & Diagnostic Laboratories• Home Care & Self-TestingBy Mode Of Purchase• Prescription Based Products• OTC ProductsBy Sample• Blood• Urine• Nasal and Oropharyngeal Swabs.